Lipikind-AS Capsule contains a combination of Atorvastatin 10 mg and Aspirin 75 mg, formulated to manage cardiovascular risk factors effectively. Atorvastatin, a potent HMG-CoA reductase inhibitor, works by reducing low-density lipoprotein cholesterol (LDL-C) and triglycerides while modestly increasing high-density lipoprotein cholesterol (HDL-C), thereby aiding in the prevention of atherosclerosis and associated cardiovascular events. Aspirin, an antiplatelet agent, irreversibly inhibits cyclooxygenase, leading to decreased thromboxane A2 production and subsequent reduction in platelet aggregation. This dual action of lipid-lowering and antithrombotic effects makes Lipikind-AS Capsule suitable for patients at high risk of myocardial infarction, stroke, and other thrombotic complications, particularly those with established coronary artery disease or multiple risk factors. The combination therapy enhances patient compliance by simplifying the medication regimen. Lipikind-AS should be used under medical supervision, with periodic monitoring of lipid profiles, liver function tests, and bleeding parameters. Contraindications include hypersensitivity to either component, active peptic ulcer disease, severe hepatic impairment, and bleeding disorders. Caution is advised in patients with a history of gastrointestinal bleeding or concurrent use of other anticoagulants. Adherence to prescribed dosage and lifestyle modifications is essential for optimal therapeutic outcomes.